OverviewChartNewsTraderScreen

HSBC Knock-Out GLPGF/  DE000HG2MUR7  /

Frankfurt Zert./HSBC
24/01/2025  21:35:18 Chg.+0.010 Bid21:55:48 Ask24/01/2025 Underlying Strike price Expiration date Option type
3.690EUR +0.27% 3.700
Bid Size: 15,000		 -
Ask Size: -		 Galapagos N.V. 59.0483 - 31/12/2078 Put
Newsfile Corp 25/10/2024 Trundless Expands Focus on Ecuador as a Top 2024 Travel Spot for Nature and Culture
Newsfile Corp 06/09/2024 Metropolitan Touring Achieves Sustainability Benchmark with Carbon-Neutral Commitment
GlobeNewswire 27/08/2024 Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy
GlobeNewswire 27/08/2024 Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy
GlobeNewswire 23/08/2024 Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, G...
GlobeNewswire 22/08/2024 Inspirato Introduces “Inspirato Invited”
GlobeNewswire 20/08/2024 Galapagos receives transparency notification from FMR LLC
GlobeNewswire 01/08/2024 Galapagos reports half-year 2024 financial results and provides second quarter business update
GlobeNewswire 14/06/2024 Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at...
GlobeNewswire 30/05/2024 Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively licens...
GlobeNewswire 16/05/2024 Galapagos creates new subscription right plans
GlobeNewswire 15/05/2024 Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ dec...
GlobeNewswire 02/05/2024 Galapagos reports first quarter 2024 financial results  
GlobeNewswire 30/04/2024 Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and E...
GlobeNewswire 04/04/2024 Galapagos showcases innovative approach in hematological cancer care with clinical and translational...
GlobeNewswire 28/03/2024 Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
GlobeNewswire 26/03/2024 Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
GlobeNewswire 22/02/2024 Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Cl...
GlobeNewswire 22/02/2024 Galapagos announces full year 2023 results and outlook for 2024
GlobeNewswire 15/02/2024 Galapagos presents at EBMT-EHA annual meeting 2024
GlobeNewswire 05/02/2024 NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer
GlobeNewswire 31/01/2024 Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
GlobeNewswire 04/01/2024 Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further exp...
GlobeNewswire 03/01/2024 Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule dru...
GlobeNewswire 02/01/2024 Galapagos signs agreement to transfer Jyseleca® business to Alfasigma